Lung cancer is a field full of progress, as exemplified here by Sanjay Popat, PhD, MBBS, FRCP, of the Royal Marsden NHS Foundation Trust, London, UK. Dr Popat highlights the developments and future treatment landscape in this space, covering immunochemotherapy combinations, precision medicine and biomarkers. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.